Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study

F Lordick, I Haffner, B Luber, D Maier, E Raimundez, J Hasenauer, A Kretzschmar, LF von Weikersthal, M Ahlborn, JR Knorrenschild, Gabriele Siegler, B Rau, S Fuxius, T Decker, K Schierle, C Wittekind

Research output: Contribution to journalpublished Abstract (Journal)peer-review

2 Citations (Web of Science)
Original languageEnglish
Issue number13
Publication statusPublished - 2018
EventAnnual Meeting of the American-Association-for-Cancer-Research (AACR) - Chicago, IL
Duration: 14 Apr 201818 Apr 2018

Cite this